Human Embryonic Stem Cells Market Analysis By Growth …

The MarketWatch News Department was not involved in the creation of this content.

Japan, Japan, Tue, 09 Feb 2021 02:20:38 / Comserve Inc. / -- The report analyzes the international markets including development trends, competitive landscape analysis, investment plan, business strategy, opportunity, and key regions development status.

The government funding for the development of regenerative medicine has been increasing in most developed countries, because of its applications in organ transplantation, tissue engineering, and various other applications. In the United States, two major government agencies, National Institutes of Health (NIH) and California Institute of Regenerative Medicine (CIRM), fund almost all the translational researches and regenerative medicine development in the country. It is estimated that the United States government invests around USD 800-900 million every year in stem cell research. Additionally, other factors such as the high prevalence of cardiac and malignant diseases, and rising demand for regenerative medicines are expected to drive the market.

Key Market Trends

Stem Cell Biology Research Segment is Expected to Show Better Growth in the Forecast Years

Based on the application, it is segmented into regenerative medicine, stem cell biology research, tissue engineering, and toxicology testing. Stem cell biology research will show better growth, owing to the high prevalence of cardiac and malignant diseases. An article published by the ISSCR (International Society for Stem Cell Research) reported that the stem cells hold potential for the treatment of Parkinson's disease in humans. Recently, one of the market players, International Stem Cell Corporation (ISCO), received the patent covering methods for generating HLA homozygous parthenogenetic human stem cell lines from unfertilized eggs. The patent was issued in Australia. Furthermore, to boost the pace of stem cell research, the government is providing funding opportunities to researchers. Thus, owing to these factors, the market studied is expected to witness a high growth rate over the forecast period.

Click Here to Download Sample Report >> https://www.sdki.jp/sample-request-81122

North America Dominates the Human Embryonic Stem Cells Market

The human embryonic stem cells market is expected to dominate in the North America region owing to extensive research activities, along with high burden of chronic diseases and genetic disorders in the region. The United States also shows a high incidence of other diseases, such as diabetes, heart disease, renal failure, and osteoporosis. Human embryonic stem cells have high potential for use in treatment and may become a standard of care for these diseases. Additionally, the FDA has approved clinical trials, which indicated the use of stem cells. Hence, these factors are expected to influence the growth of the human embryonic stem cells market over the forecast period.

Competitive Landscape

The global players into the human embryonic stem cells market are Becton, Dickinson and Company, Cynata Therapeutics Limited, ESI BIO, Geron Corporation, International Stem Cell Corporation, Merck KGaA, PromoCell GmbH, STEMCELL Technologies Inc, Thermo Fisher Scientific and ViaCyte, Inc.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format - Report customization as per the client's requirements - 3 months of analyst support

Request For Full Report >>https://www.sdki.jp/sample-request-81122

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 High Prevalence of Cardiac and Malignant Diseases 4.2.2 Rising Demand for Regenerative Medicines 4.2.3 Increasing Support from Governments and Government and Private Institutions 4.3 Market Restraints 4.3.1 High Cost of the Procedure 4.3.2 Stringent Regulatory Guidelines 4.4 Porter's Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Application 5.1.1 Regenerative Medicine 5.1.2 Stem Cell Biology Research 5.1.3 Tissue Engineering 5.1.4 Toxicology Testing 5.2 Geography 5.2.1 North America 5.2.1.1 United States 5.2.1.2 Canada 5.2.1.3 Mexico 5.2.2 Europe 5.2.2.1 Germany 5.2.2.2 United Kingdom 5.2.2.3 France 5.2.2.4 Italy 5.2.2.5 Spain 5.2.2.6 Rest of Europe 5.2.3 Asia-Pacific 5.2.3.1 China 5.2.3.2 Japan 5.2.3.3 India 5.2.3.4 Australia 5.2.3.5 South Korea 5.2.3.6 Rest of Asia-Pacific 5.2.4 Rest of World

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Becton, Dickinson and Company 6.1.2 Cynata Therapeutics Limited 6.1.3 ESI BIO 6.1.4 Geron Corporation 6.1.5 International Stem Cell Corporation 6.1.6 Merck KGaA 6.1.7 PromoCell GmbH 6.1.8 STEMCELL Technologies Inc 6.1.9 Thermo Fisher Scientific 6.1.10 ViaCyte, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

For more information, please contact:

Shibuya Data Count Email: sales@sdki.jp Tel: + 81 3 45720790

The post Human Embryonic Stem Cells Market Analysis By Growth, Emerging Trends , Future Opportunities and Forecast to 2025 appeared first on Comserveonline.

COMTEX_380504484/2652/2021-02-09T02:22:14

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

The MarketWatch News Department was not involved in the creation of this content.

Excerpt from:
Human Embryonic Stem Cells Market Analysis By Growth ...

Pros and Cons of embryonic stem cells – Pros an Cons

Embryonic stem cells are cells that are found in living things and can regenerate and grow into other cells. This they do them by growing and repairing inside their host so long as the host is still living. These cells are known to be taken from 3-5 old embryos of blastocysts. Their major source is unfertilized in vitro eggs and they are acquired from donors who permit the cells to be used for research. These cells are crucial for they are used for many things. Some of the uses include; getting information on cell development and as an ingredient in the creation of drugs that cure diseases such as cardiovascular and diabetes.

Pros

1. considered lifeless: Many specialists argue that the embryos used for this research should not be viewed as persons. The reason being the embryos have not taken any human form that is they do not possess any physical and psychological properties that make them resemble a human being. Besides they also argue that the embryo has not been implanted in the uterus therefore cannot be regarded as human and the fact that their survival rate is very narrow and therefore they are not to be considered as living persons at any time.

2. Offer many medical possibilities: The stem cells are known to be undifferentiated that is they can be used in all parts of the body and can cure very many diseases. Their ability to cure as many diseases results from the fact that the embryonic stem cells can be used to generate other cells.

3. Progress in cancer research: Specialists conclude that the embryonic stem cells are very similar to the cancer cells which makes it easy to study them. Besides, their study since they are the same as the cancerous cells will help in the development of cancer drugs and other treatments.

4. Easily available: Most of these embryos can be attained from specific in vitro fertilization clinic centers. Many types of research have been made possible due to the availability of embryonic stem cells.

5. Flexibility: The major advantage of embryonic stem cells is their ability to create many more cells. This is useful in the making of drugs as well as treatment of some illness and lastly best used in research to find medication for other diseases.

6. The central nervous system is not formed yet: The embryo at the time of harvest is around two weeks which means that the nervous system has not yet developed. It is at this stage too that specialists also cant tell if the embryo is to develop into a fetus. This justifies in a way that since these embryos do not have senses yet, that means it is okay to harvest them and use them for research.

7. Harvested from unused embryos: Consent from donors is the key to the harvesting of the stem cells. Some people may think its unethical because of using fertilized eggs but since consent is involved that outweighs that thought. This should be seen as an act of good faith since it is the usage of embryos that were to be disposed of to create medical treatments.

Cons

1. High rejection rates: Most of the already done tests with the embryonic stem cells show that some embryonic stem cell therapies have resulted in too many health problems. It has been proven that the cells have been rejected severely as some of them do not respond as intended. Some of these cells have caused major impacts such as causing tumors.

2. Difficult to obtain: A lot of things are required to ensure that the embryonic stem cells are obtained, some of these include the fact that one has to wait for the embryo to grow in culture and several other months for it to fully mature to the stage where now it can be used.

3. Uncertain long-term side effects: Most of the treatments done with the embryonic stem cells are risky in such a way that the specialists are not certain of any future risk and how dangerous they could be. At the moment only short term benefits are enjoyed and research to show the long term side effects are still underway.

4. Harvesting requires the death of an embryo: Obtaining any embryonic stem cell requires one to get rid of the life within an embryo. This has brought ethical issues of the obtaining process despite the advantage that is brought about by the research.

5. They are expensive to obtain: The process of obtaining the stem cells is very expensive as it is estimated that harvesting an embryonic stem cell may cost $2,000. The therapies also ae as costly and this is available for only people with the ability to afford the medical service.

6. Difficulty in differentiating specialized lines: The process used by specialists to create the embryonic stem cells is insufficient.

7. Causes tumors: This is brought about by the extraction of the embryonic stem cells of undifferentiated culture which are prepared for tissue transplantation. This also can lead to the development of cancerous cells.

8. Risk of female donors: Female donors who consent to give out their embryos risk getting sick. Most of the research done however has shown that most of the donors consent to giving out their embryos rather than see them being discarded.

In conclusion, embryonic stem cells have been used by scientists to research on possible medications of cancer since the cells resemble the cancerous cells. The generative property of these cells gives them their unique advantage over other types of stem cells. A lot of debates have been done due to the thought that an embryo is a living thing and using it for the experiment would be inhuman. This, however, has been countered by the fact that people voluntarily give consent for their embryos to be used and the uses for the cells are for improving humanity rather than causing damage.

Read the original:
Pros and Cons of embryonic stem cells - Pros an Cons

Worldwide Cell Therapy Industry to 2027 – Profiling Allosource, Medipost and Mesoblast Among Others – PRNewswire

DUBLIN, Feb. 9, 2021 /PRNewswire/ -- The "Cell Therapy Market by Cell Type, Therapy Type, Therapeutic Area, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global cell therapy market accounted for $7,754. 89 million in 2019, and is expected to reach $48,115. 40 million by 2027, registering a CAGR of 25. 6% from 2020 to 2027.

Cell therapy involves administration of somatic cell preparations for treatment of diseases or traumatic damages. Cell therapy aims to introduce new, healthy cells into a patient's body to replace diseased or missing ones.

This is attributed to the fact that specialized cells, such as brain cells, are difficult to obtain from human body. In addition, specialized cells typically have a limited ability to multiply, making it difficult to produce sufficient number of cells required for certain cell therapies. Some of these issues can be overcome through the use of stem cells. In addition, cells such as blood and bone marrow cells, mature, immature & solid tissue cells, adult stem cells, and embryonic stem cells are widely used in cell therapy procedures.

Moreover, transplanted cells including induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are divided broadly into two main groups including autologous cells and non-autologous cells. Development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. Furthermore, automation in adult stem cells and cord blood processing and storage are the key technological advancements that fuel growth of the market for cell therapy.

In addition, growth in aging patient population, The rise in cell therapy transplantations globally, and surge in disease awareness drive growth of the global cell therapy market. Furthermore, The rise in adoption of human cells over animal cells for cell therapeutics research, technological advancements in field of cell therapy, and increase in incidences of diseases such as cancer, cardiac abnormalities, and organ failure are the key factors that drive growth of the global market.

Moreover, implementation of stringent government regulations regarding the use of cell therapy is anticipated to restrict growth of the market. On the contrary, surge in number of regulations to promote stem cell therapy and increase in funds for research in developing countries are expected to offer lucrative opportunities to the market in the future.

The global cell therapy market is categorized on the basis of therapy type, therapeutic area, cell type, end user, and region. On the basis of therapy type, the market is segregated into autologous and allogenic. By therapeutics, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others.

The global cell therapy market is categorized on the basis of therapy type, therapeutic, cell type, end user and region. On the basis of therapy type, the market is segregated into autologous and allogenic. By therapeutic area, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others. On the basis of cell type, it is segregated into stem cell therapy and non-stem cell type. On the basis of end user, it is segregated into hospital & clinics and academic & research institutes. On the basis of region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

Key Topics Covered:

Chapter 1: Introduction 1.1. Report Description 1.2. Key Benefits for Stakeholders 1.3. Key Market Segments 1.4. Research Methodology 1.4.1. Secondary Research 1.4.2. Primary Research 1.4.3. Analyst Tools & Models

Chapter 2: Executive Summary 2.1. Key Findings of the Study 2.2. Cxo Perspective

Chapter 3: Market Overview 3.1. Market Definition and Scope 3.2. Key Findings 3.2.1. Top Player Positioning 3.2.2. Top Investment Pockets 3.2.3. Top Winning Strategies 3.3. Porter's Five Forces Analysis 3.4. Impact Analysis 3.4.1. Drivers 3.4.1.1. Technological Advancements in the Field of Cell Therapy 3.4.1.2. The Rise in Number of Cell Therapy Clinical Studies 3.4.1.3. The Rise in Adoption of Regenerative Medicine 3.4.2. Restraint 3.4.2.1. Developing Stage and Pricing 3.4.3. Opportunity 3.4.3.1. High Growth Potential in Emerging Markets 3.5. Impact of Covid-19 on Cell Therapy Market

Chapter 4: Cell Therapy Market, by Cell Type 4.1. Overview 4.1.1. Market Size and Forecast 4.2. Stem Cell 4.2.1. Key Market Trends and Opportunities 4.2.2. Market Size and Forecast, by Region 4.2.3. Market Size and Forecast, by Type 4.2.3.1. Bone Marrow, Market Size and Forecast 4.2.3.2. Blood, Market Size and Forecast 4.2.3.3. Umbilical Cord-Derived, Market Size and Forecast 4.2.3.4. Adipose-Derived Stem Cell, Market Size and Forecast 4.2.3.5. Others (Placenta, and Nonspecific Cells), Market Size and Forecast 4.3. Non-Stem Cell 4.3.1. Key Market Trends and Opportunities 4.3.2. Market Size and Forecast, by Region

Chapter 5: Cell Therapy Market, by Therapy Type 5.1. Overview 5.1.1. Market Size and Forecast 5.2. Autologous 5.2.1. Key Market Trends and Opportunities 5.2.2. Market Size and Forecast, by Region 5.2.3. Market Analysis, by Country 5.3. Allogeneic 5.3.1. Key Market Trends and Opportunities 5.3.2. Market Size and Forecast, by Region 5.3.3. Market Analysis, by Country

Chapter 6: Cell Therapy Market, by Therapeutic Area 6.1. Overview 6.1.1. Market Size and Forecast 6.2. Malignancies 6.2.1. Market Size and Forecast, by Region 6.2.2. Market Analysis, by Country 6.3. Musculoskeletal Disorders 6.3.1. Market Size and Forecast, by Region 6.3.2. Market Analysis, by Country 6.4. Autoimmune Disorders 6.4.1. Market Size and Forecast, by Region 6.4.2. Market Analysis, by Country 6.5. Dermatology 6.5.1. Market Size and Forecast, by Region 6.5.2. Market Analysis, by Country 6.6. Others 6.6.1. Market Size and Forecast, by Region 6.6.2. Market Analysis, by Country

Chapter 7: Cell Therapy Market, by End-user 7.1. Overview 7.1.1. Market Size and Forecast 7.2. Hospitals & Clinics 7.2.1. Key Market Trends and Opportunities 7.2.2. Market Size and Forecast, by Region 7.2.3. Market Analysis, by Country 7.3. Academic & Research Institutes 7.3.1. Key Market Trends and Opportunities 7.3.2. Market Size and Forecast, by Region 7.3.3. Market Analysis, by Country

Chapter 8: Cell Therapy Market, by Region 8.1. Overview 8.2. North America 8.3. Europe 8.4. Asia-Pacific 8.5. LAMEA

Chapter 9: Company Profiles 9.1. Allosource 9.1.1. Company Overview 9.1.2. Company Snapshot 9.1.3. Operating Business Segments 9.1.4. Product Portfolio 9.1.5. Key Strategic Moves and Developments 9.2. Cells for Cells 9.2.1. Company Overview 9.2.2. Company Snapshot 9.2.3. Operating Business Segments 9.2.4. Product Portfolio 9.3. Holostem Terapie Avanzate Srl 9.3.1. Company Overview 9.3.2. Company Snapshot 9.3.3. Operating Business Segments 9.3.4. Product Portfolio 9.4. Jcr Pharmaceuticals Co. Ltd. 9.4.1. Company Overview 9.4.2. Company Snapshot 9.4.3. Operating Business Segments 9.4.4. Product Portfolio 9.4.5. Business Performance 9.4.6. Key Strategic Moves and Developments 9.5. Kolon Tissuegene, Inc. 9.5.1. Company Overview 9.5.2. Company Snapshot 9.5.3. Operating Business Segments 9.5.4. Product Portfolio 9.5.5. Key Strategic Moves and Developments 9.6. Medipost Co. Ltd. 9.6.1. Company Overview 9.6.2. Company Snapshot 9.6.3. Operating Business Segments 9.6.4. Product Portfolio 9.6.5. Business Performance 9.7. Mesoblast Ltd 9.7.1. Company Overview 9.7.2. Company Snapshot 9.7.3. Operating Business Segments 9.7.4. Product Portfolio 9.7.5. Business Performance 9.8. Nuvasive, Inc. 9.8.1. Company Overview 9.8.2. Company Snapshot 9.8.3. Operating Business Segments 9.8.4. Product Portfolio 9.8.5. Business Performance 9.9. Osiris Therapeutics, Inc. 9.9.1. Company Overview 9.9.2. Company Snapshot 9.9.3. Operating Business Segments 9.9.4. Product Portfolio 9.10. Stemedica Cell Technologies, Inc. 9.10.1. Company Overview 9.10.2. Company Snapshot 9.10.3. Operating Business Segments 9.10.4. Product Portfolio

For more information about this report visit https://www.researchandmarkets.com/r/shw12n

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

More here:
Worldwide Cell Therapy Industry to 2027 - Profiling Allosource, Medipost and Mesoblast Among Others - PRNewswire